Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00113620 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy
A Phase 3 study of Pain and Diabetic Neuropathy, sponsored by Avanir Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
- 20
- Study locations
NCT00113620 is a Phase 3 study of Pain and Diabetic Neuropathy that has completed, run by Avanir Pharmaceuticals. The registered enrollment target is 450 participants, above the 303-participant average among 374 other Pain trials with a reported enrollment target (49% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT00113620, a Phase 3 study of Pain and Diabetic Neuropathy, has completed, sponsored by Avanir Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether dextromethorphan (Neurodex) and quinidine are effective in the treatment of pain of diabetic neuropathy.
Conditions Studied
Interventions
- DRUG Neurodex
Study Locations (20)
Florida
- Tampa Bay Medical Research - Clearwater
- University Clinical Research - DeLand - DeLand
- The Center for Diabetes and Endocrine Care - Hollywood
- FPA Clinical Research - Kissimmee
- Suncoast Neuroscience Associates, Inc. - St. Petersburg
- Neurology Clinical Research, Inc. - Sunrise
- Laszlo J. Mate, MD - West Palm Beach
California
- Bay Area Foot Care - Castro Valley
- South Bay Clinical Research Inc. - Inglewood
- Pacific Sleep Medicine Services, Inc. - Los Angeles
- Pacific Sleep Medicine Services, Inc. - Palm Springs
- Northern California Research Group - Sacramento
- Diablo Clinical Research, Inc. - Walnut Creek
Arizona
- Pivotal Research Centers - Mesa
- Dedicate Clinical Research, Inc. - Sun City
Arkansas
- Central Arkansas Research - Hot Springs
- Research Solutions - Jonesboro
Indiana
- Medisphere Medical Research Center, LLC - Evansville
- Investigative Clinical Reserach of Indiana, LLC - Indianapolis
Hawaii
- East-West Medical Research Institute - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2005-07 |
| Est. Completion | 2007-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00113620
The ClinicalTrials.gov registry entry for NCT00113620 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 303-participant average among 374 other Pain trials with a reported enrollment target (49% higher). The listed sponsor is Avanir Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 1 intervention - of which Neurodex is the first listed.
NCT00113620 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT00113620 about?
NCT00113620 is a clinical study titled "Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy". The purpose of this study is to determine whether dextromethorphan (Neurodex) and quinidine are effective in the treatment of pain of diabetic neuropathy.
What is the current status of trial NCT00113620?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2005-07. Estimated completion is 2007-02.
What conditions does trial NCT00113620 study?
This clinical trial studies the following conditions: Pain, Diabetic Neuropathy.
What interventions are being tested in trial NCT00113620?
The interventions under investigation include: Neurodex (DRUG).
Who is sponsoring clinical trial NCT00113620?
This trial is sponsored by Avanir Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00113620 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures: A Pragmatic, Randomized Controlled Trial
RECRUITING · Phase 3
-
Opioid-Free Orthopaedics
RECRUITING · Phase 3
-
Suzetrigine in Total Hip Arthroplasty
RECRUITING · Phase 3
-
Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits
RECRUITING · Phase 3
-
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
RECRUITING · Phase 3
-
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.